Company intelligence / Profile preview

Cairn Therapeutics

Tucson, Arizona, United Statescairntherapeutics.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Cairn's lead candidate CT-262 shows exceptional potency with dramatic efficacy, broad applicability to most solid tumor types and hematological tumors, better tolerability than other drugs in its class with low toxicity and low myelosuppression, and is not subject to traditional mechanisms of resistance.

Therapeutic areas: OncologyHematology
Modalities: Small moleculesDNA binding agents
Industry: Biotech

Drug pipeline

3 assets

CT-262

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cairn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cairn Therapeutics.

Explore the full profile